作者
Scott D Solomon, Muthiah Vaduganathan, Brian L. Claggett, Milton Packer, Michael Zile, Karl Swedberg, Jean Rouleau, Marc A. Pfeffer, Akshay Desai, Lars H. Lund, Lars Kober, Inder Anand, Nancy Sweitzer, Gerard Linssen, Bela Merkely, Juan Luis Arango, Dragos Vinereanu, Chen-Huan Chen, Michele Senni, Antonio Sibulo, Sergey Boytsov, Victor Shi, Adel Rizkala, Martin Lefkowitz, John JV McMurray
发表日期
2020/2/4
期刊
Circulation
卷号
141
期号
5
页码范围
352-361
出版商
Lippincott Williams & Wilkins
简介
Background
While disease-modifying therapies exist for heart failure (HF) with reduced left ventricular ejection fraction (LVEF), few options are available for patients in the higher range of LVEF (>40%). Sacubitril/valsartan has been compared with a renin-angiotensin-aldosterone–system inhibitor alone in 2 similarly designed clinical trials of patients with reduced and preserved LVEF, permitting examination of its effects across the full spectrum of LVEF.
Methods
We combined data from PARADIGM-HF (LVEF eligibility≤40%; n=8399) and PARAGON-HF (LVEF eligibility≥45%; n=4796) in a prespecified pooled analysis. We divided randomized patients into LVEF categories: ≤22.5% (n=1269), >22.5% to 32.5% (n=3987), >32.5% to 42.5% (n=3143), > 42.5% to 52.5% (n=1427), > 52.5% to 62.5% (n=2166), and >62.5% (n=1202). We assessed time to first cardiovascular death and HF hospitalization, its components …
学术搜索中的文章
SD Solomon, M Vaduganathan, B L. Claggett… - Circulation, 2020